Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.67 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | RAF1 | P04049 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25081170 | 0.94 | KRAS (0.66) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL30254328 | 0.94 | KRAS (0.66) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL30254305 | 0.94 | KRAS (0.66) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL25081174 | 0.94 | KRAS (0.66) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL30254382 | 0.94 | KRAS (0.66) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL30254277 | 0.93 | KRAS (0.76) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL25080985 | 0.93 | KRAS (0.76) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL25081184 | 0.89 | KRAS (0.83) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL25080934 | 0.89 | KRAS (0.83) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL30254106 | 0.89 | KRAS (0.83) | KRASMAPK3MAPK1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019377-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-01-16 | — | — | US | disclosed |
| EP-4387967-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023020519-A9 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023020519-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019377-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | CYP11B2, CYP21A2, CYP11B1 | KRAS 2838/4885MAPK3 2751/4885MAPK1 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.